COSM News & Events

Cosmos Health announced a significant expansion of its United Kingdom retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4%, is now available through Tesco.

Cosmos Health announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin. The Company's digital assets program has so far been centered on Ethereum. While Ethereum will continue to serve as a key pillar of the program, the addition of Bitcoin represents a strategic evolution intended to broaden exposure across established digital assets. Cosmos Health is also selectively evaluating the inclusion of additional cryptocurrencies within this framework, based on market conditions and alignment with the Company's broader financial strategy. To date, Cosmos Health has invested a total of $2.5M in cryptocurrencies, reflecting the combined value of its Ethereum holdings and the newly completed Bitcoin investment.

Cosmos Health announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution subsidiary in Greece. "During 2025, Cosmofarm added nearly 100 new pharmacy customers, representing a weighted average increase of approximately 20% in its active customer base. This growth was accompanied by improved unit economics, with annual revenue per customer increasing by approximately 12% and profitability per customer improving by approximately 14%, driven by enhanced route density, optimized order execution, and increasing operational leverage. Based on current onboarding activity and demand trends, management expects customer growth in 2026 to continue at similar or higher rates. To further strengthen service quality and last-mile delivery performance, Cosmofarm introduced three new delivery routes within the Attica region, expanding geographic coverage and delivery frequency across one of Greece's most densely populated pharmaceutical markets. Cosmofarm's operating model is supported by multi-year, multi-million investments in automation and logistics infrastructure, including advanced ROWA and A-frame robotic systems for procurement, inventory management, and order fulfillment. A further capital investment program of approximately $1 million is currently underway, continuing prior initiatives to expand robotic capacity and throughput... the master plan of the expanded ROWA and A-frame robotic picking line, highlighting an integrated automation layout designed to materially increase processing capacity, enhance accuracy and speed, and support incremental annual revenue potential of approximately $40 million through expanded distribution capability," the company stated.

Cosmos Health 's wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical. Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with applicable regulatory requirements. The product will be distributed and commercially promoted in the Greek market by Libytec Pharmaceutical S.A., with the agreement providing for firm minimum committed production volumes of 591,500 units and expected cumulative production volumes over a five-year period anticipated to exceed 1.2 million units, subject to market demand and commercial performance.